Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects

[1]  F. Massari,et al.  Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis , 2021, Expert review of gastroenterology & hepatology.

[2]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[3]  R. Roskoski.  Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. , 2021, Pharmacological research.

[4]  A. Rubio‐Tapia,et al.  AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor (ICI) Colitis and Hepatitis: Expert Review. , 2020, Gastroenterology.

[5]  Yan Zhao,et al.  Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[6]  R. Greil,et al.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.

[7]  S. Paydaş.  Management of adverse effects/toxicity of ibrutinib. , 2019, Critical reviews in oncology/hematology.

[8]  N. Malhotra,et al.  Immune checkpoint inhibitor-induced colitis: A comprehensive review , 2019, World journal of clinical cases.

[9]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[10]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[11]  K. Shohdy,et al.  Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review. , 2019, Critical reviews in oncology/hematology.

[12]  H. Rugo,et al.  The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea , 2019, Breast Cancer Research and Treatment.

[13]  R. Bresalier,et al.  Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. , 2018, Inflammatory bowel diseases.

[14]  Shun-Fa Yang,et al.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies , 2018, Cancer management and research.

[15]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[16]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[17]  Sung-Bae Kim,et al.  Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[18]  A. Tsao.  Osimertinib for Untreated , 2017 .

[19]  Ying Cheng,et al.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[20]  R. Larson,et al.  Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study , 2017, The Lancet. Oncology.

[21]  J. Dipersio,et al.  Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial , 2017, Journal of Hematology & Oncology.

[22]  I. Nagtegaal,et al.  Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa? , 2016, Acta oncologica.

[23]  Chun-Ming Tsai,et al.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Berardi,et al.  Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta‐analysis of clinical trials , 2014, International journal of cancer.

[25]  C. Walko,et al.  Regorafenib , 2013, Reactions Weekly.

[26]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[28]  N. Pavlidis,et al.  Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management , 2012, Annals of gastroenterology.

[29]  Thomas Krause,et al.  Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. , 2012, The Lancet. Oncology.

[30]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[31]  J. Robert.  [Tyrosine kinase inhibitors]. , 2011, Bulletin du cancer.

[32]  Michael Thomas,et al.  Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. van Hillegersberg,et al.  Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review , 2010, Angiogenesis.

[34]  Eric B Haura,et al.  Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Hans-Peter Lipp,et al.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. , 2009, Current drug metabolism.

[36]  J. Schoen,et al.  Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma , 2009, Investigational New Drugs.

[37]  B. Mehić,et al.  Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer. , 2008, Bosnian journal of basic medical sciences.

[38]  S. Jung,et al.  Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment. , 2008, World journal of gastroenterology.

[39]  J. Soria,et al.  Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy , 2008, Nature Clinical Practice Oncology.

[40]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[41]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[42]  J. Blay,et al.  Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). , 2006, European journal of cancer.

[43]  R. Bruno,et al.  Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer , 2006, Clinical pharmacology and therapeutics.

[44]  Y. Komiyama,et al.  Aspirin reduces adverse effects of gefitinib , 2006, Anti-cancer drugs.

[45]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[46]  K. Barrett,et al.  Phosphatidylinositol 3-Kinase Mediates the Inhibitory Effect of Epidermal Growth Factor on Calcium-dependent Chloride Secretion* , 1996, The Journal of Biological Chemistry.

[47]  A. Saga,et al.  [Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors]. , 2014, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[48]  A. Tsao.  Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) , 2012 .

[49]  M. Kris,et al.  Practical management of patients with non-small-cell lung cancer treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  L. Boyajian-O’Neill,et al.  Practical Management , 2004 .

[51]  D. Kohn.  Long-term treatment , 1993 .